• Home
  • RA2Day Anniversary Special

In the past decade, more than 25% of drug approvals were for treatment of cancer. Much can be learned from the regulatory pathways taken. Have regulatory initiatives to speed up the authorization of cancer drugs lived up to the expectations?

In RA2day, we evaluate regulatory performance and answer key questions. Is time to get to the market decreased? How is the regulatory toolbox used? What are the differences between EU and US? See how data from the Zwiers 2010-2020 oncology database substantiate the impact of regulatory affairs on approvals in general and for oncology drugs in particular.

 But also…be prepared to expect the unexpected … .


Overview of a decade of new oncology drugs


  • Regulatory approvals: cancer drugs reaching the market

  • EU vs US: difference in approval times

  • Impact of clinical development time on approval


  • Regulatory toolbox: opportunities for faster approval

  • Advisory Committee Meeting (US) vs Scientific Advisory Group (EU)

 Ready to learn more about the impact of Regulatory Affairs in the oncology field?

Join us in celebrating 10 years of solid RA/PV service!

Click here for the full programme


Including lunch | Networking opportunity | €100 (ex VAT) fee for charity


 Register now!